ALXN1830
Phase 2Small molecule
AstraZenecaALXN1830 is one of 68 small molecule programs targeting Pemphigus. It is currently in Phase 2.
3
Indications
7
Total Trials
0
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Myasthenia Gravis
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Ultomiris
AstraZenecaPhase 3
Vyvgart
ArgenxPhase 3
Zilbrysq
UCBPhase 3
Soliris
AstraZenecaPhase 3
Cellcept
RochePhase 3
Fabhalta
Johnson & JohnsonPhase 3
ENSPRYNG
RochePhase 3
Arava
SanofiPhase 3
Rhapsido
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Warm Autoimmune Hemolytic Anemia3 trials
Adult2 trials
Pemphigus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALXN1830. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company